Company intelligence / Profile preview

Prinston Pharmaceutical

Somerset, New Jersey, United Statesprinstonpharm.com ↗

Ownership: Private
Employees: ~87
Development stage: Commercial

Overview

Prinston Pharmaceutical currently markets about 90 products in the US, with approximately 40 products pending FDA approval. They have a robust R&D pipeline of potential new products. Their first product, Benazepril, was launched in 2010, and they have since launched numerous other generic medications.

Therapeutic areas: OncologyCardiovascularNeurologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Beyond the preview

Go deeper on Prinston Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prinston Pharmaceutical.

Explore the full profile